Clinical Trials Sponsored by Iconic Therapeutics, Inc.

Total 3114 results

Iconic Therapeutics, Inc.

Completed

Safety and Tolerability Study for Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Iconic Therapeutics, Inc.

Completed

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (EMERGE)

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Iconic Therapeutics, Inc.

Completed

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

Uveal Melanoma | Choroid Neoplasm

United States
Iconic Therapeutics, Inc.

Terminated

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (DECO)

Choroidal Neovascularization | Wet Macular Degeneration

United States
Onconic Therapeutics Inc.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Ovarian Cancer
Onconic Therapeutics Inc.

Recruiting

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Erosive Esophagitis

Korea, Republic of
Onconic Therapeutics Inc.

Completed

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

GERD

Korea, Republic of
Onconic Therapeutics Inc.

Completed

Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian

Anti-Ulcer Agents

Korea, Republic of
Onconic Therapeutics Inc.

Not yet recruiting

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma
Onconic Therapeutics Inc.

Completed

Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Healthy

Korea, Republic of
Onconic Therapeutics Inc.

Not yet recruiting

Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers

Healthy

Korea, Republic of
Onconic Therapeutics Inc.

Not yet recruiting

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Gastric Ulcer
Onconic Therapeutics Inc.

Completed

Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

Helicobacter Pylori Associated Gastrointestinal Disease

Korea, Republic of
Cionic, Inc.

Recruiting

Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting

United States
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome

United States, Brazil, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, South Africa, Spain, United Kingdom
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Cardiovascular Disease | Elevated Lipoprotein(a)

United States, Canada, Denmark, Germany, Netherlands
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Renal Impairment

United States, Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

Elevated Lipoprotein(a)

Canada
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Withdrawn

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia

Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Hypertriglyceridemia

United States, Canada, France, Germany, United Kingdom, Netherlands
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Terminated

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Familial Partial Lipodystrophy

United States, Netherlands, Belgium, Brazil, Canada, Germany, Russian Federation
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

United States, Canada, Germany, Israel, Italy, South Africa, Spain, United Kingdom, Brazil, France, Netherlands
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

Familial Partial Lipodystrophy

United States
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Diabetes Mellitus, Type 2 | NAFLD | Hypertriglyceridemia | Fatty Liver, Nonalcoholic

United States, Canada
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Hypertriglyceridemia | Familial Hypercholesterolemia

Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) (BALANCE)

Familial Chylomicronemia Syndrome

United States, Israel, Spain, Italy, United Kingdom, Netherlands, Canada, Hungary, Sweden, France, Norway, Portugal, Slovakia
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Cardiovascular Diseases | Hypertriglyceridemia

United States, Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Abnormalities, Cardiovascular

United States
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Elevated Triglycerides (TG)

Canada
Cionic, Inc.

Active, not recruiting

A 12-Week Home-Based Electrical Stimulation Program for Strength in Adults With Knee Osteoarthritis

Osteoarthritis | Osteoarthritis, Knee

United States
Cionic, Inc.

Completed

Augmenting Gait in a Population Exhibiting Foot Drop With Adaptive Functional Electrical Stimulation

Foot Drop

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Lipid Metabolism, Inborn Errors | Hypobetalipoproteinemias | Hypolipoproteinemias | Hypolipopro... and other conditions

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Hypercholesterolemia | Coronary Heart Disease

South Africa, Germany, United States, United Kingdom, Canada, Czech Republic
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

Healthy Volunteer

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Hypercholesterolemia | Coronary Heart Disease

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers

Healthy Volunteer

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects (ASSIST)

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Metabolic Disorder

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease (RADICHOL II)

Coronary Artery Disease | Heterozygous Familial Hypercholesterolemia

United States, Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Canada, Brazil, Taiwan, Singapore, South Africa, United Kingdom
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia (RADICHOL 1)

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Taiwan, Brazil, Canada, South Africa, United Kingdom, Singapore
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

Healthy Volunteer

Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

Hypercholesterolemia

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

Hypercholesterolemia

Netherlands, United States
Onconic Therapeutics Inc.
Jeil Pharmaceutical Co., Ltd.

Completed

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Advanced Solid Tumors

Korea, Republic of

Clinical Trials Sponsored by Iconic Therapeutics, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations